Search

Displaying results 481 - 490 of 3917 in total
  1. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).[L42660,L42670]

    Synonyms: MVA-BN
  2. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  3. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    It was FDA approved on July 25, 2013.

  4. Drug

    Phenylephrine

    go.drugbank.com/drugs/DB00388
    ApprovedInvestigational

    Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension, dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Pheny...

    Mixtures: Doc in the Box All Day Supply, Ed Bron GpProducts: Decongestant PE Non Drowsy, Physicians Care Non-Drowsy Sinus
  5. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  6. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  7. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022. … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  8. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label].

  9. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878] … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  10. Drug

    Amodiaquine

    go.drugbank.com/drugs/DB00613
    ApprovedInvestigational

    A 4-aminoquinoquinoline compound with anti-inflammatory properties.